Joseph R Stringer

US Patent:

20220348610, Nov 3, 2022

Filed:

Jun 20, 2019

Appl. No.:

17/253764

Inventors:

- Cambridge MA, US
Nicolas Cedric Boyer - Somerville MA, US
Joseph R. Stringer - Somerville MA, US
Derek M. LaPlaca - Somerville MA, US
Ketki Ashok Dhamnaskar - Cambridge MA, US
Zhong Ma - Lexington MA, US
Jonathan C. Blain - Melrose MA, US

International Classification:

C07K 7/02

Abstract:

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

US Patent:

20230115176, Apr 13, 2023

Filed:

Mar 27, 2020

Appl. No.:

17/442246

Inventors:

- Cambridge MA, US
Bolin Geng - Andover MA, US
Michael R. Hale - Bedford MA, US
Vincent P. Galullo - South Grafton MA, US
Jayashree G. Tikhe - Brookline MA, US
Timothy Ryan Siegert - Cambridge MA, US
Alonso Ricardo - Winchester MA, US
Derek M. LaPlaca - Somerville MA, US
Douangsone D. Vadysirisack - Boston MA, US
Guo-Qing Tang - Acton MA, US
Kathleen Seyb - Wakefield MA, US
Michelle Denise Hoarty - Billerica MA, US
Jonathan C. Blain - Melrose MA, US
Joseph R. Stringer - Somerville MA, US
Yongjin Gong - Cambridge MA, US
Claudio Sturino - Montreal, CA
Shawn Gallagher-Duval - Laval, CA
Colin Diner - Laval, CA
Burcin Akgun - Montreal, CA
Qing Cao - Belmont MA, US
Douglas A. Treco - Arlington MA, US
Vaishnavi Rajagopal - Andover MA, US
Ketki Ashok Dhamnaskar - Foster City CA, US
Zhong Ma - Lexington MA, US
Susan Ashwell - Carlisle MA, US
Jennifer Davoren - Cambridge MA, US
Xiaorong Liu - Newton MA, US
Camil Sayegh - Belmont MA, US
Wenqing Xu - Brighton MA, US
Alex Lemire - Laval, CA
Audrey Belouin - Montreal, CA
Alexandria Jeanneret - Laval, CA
Andrew Hildering - Montreal, CA
Barbara Bertani - Verona, IT
Fabrizio MIcheli - Verona, IT
Bemardo Pezzati - Verona, IT
Alfonso Pozzan - Verona, IT

International Classification:

C07D 519/00
C07D 239/10
C07D 403/10
C07D 403/12
C07D 403/14
C07D 471/04

Abstract:

The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.

US Patent:

20210284694, Sep 16, 2021

Filed:

Jun 20, 2019

Appl. No.:

17/253864

Inventors:

- Rahway NJ, US
- Cambridge MA, US
Nicolas Cedric Boyer - Somerville MA, US
Joseph R. Stringer - Somerville MA, US
Derek M. LaPlaca - Somerville MA, US
Angela Dawn Kerekes - Plainfield, MA
Chengwei Wu - Ambler PA, US
Sookhee Nicole Ha - Warren NJ, US
Hyewon Youm - Berkeley Heights NJ, US
Mark W. Embrey - Harleysville PA, US
Elisabetta Bianchi - Rome, IT
Danila Branca - Pomezia, IT
Raffaele Ingenito - Pomezia, IT
Willy Costantini - Pomezia, IT
Alessia Santoprete - Rome, IT
Roberto Costante - Silvi, IT
Immacolata Conte - Pomezia, IT
Stefania Colarusso - Rome, IT
Eric J. Gilbert - Scotch Plains NJ, US
Aurash Shahripour - Gaithersburg MD, US
Yusheng Xiong - Plainsboro NJ, US

International Classification:

C07K 7/64

Abstract:

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.